an2therapeutics.com (ANTX) Cash Funds Calculated per Share

AN2 Bio - graphic logo of issuer ANTX

The use of external CDMO facilities minimizes the risk of production downtime in California for AN2 Therapeutics, Inc. (ANTX). Cash per share clearly illustrates current liquidity, with the latest value recorded as 1.71. AN2 Therapeutics, Inc. (ANTX) develops antibiotics against resistant bacteria to ensure stable sales. Patent protection and FDA orphan drug status create significant barriers to entry for new market players.

AN2 Therapeutics (ANTX): Cash Funds per Share from 04/28/2023 to 11/21/2026

ANTX (an2therapeutics.com): analytical breakdowns and indicator data

- current price and projected stock value:
Basic company analysis:ANTX, AN2 Bio
Signature product of AN2 Therapeutics, Inc.

Cash per share reflects the volume of an organization's liquid assets allocated to a single security. This cash per share valuation is based on a daily recalculation of cash reserves, eliminating reporting time lags. Growth in this metric confirms financial stability and reduces default risk. For AN2 Therapeutics, Inc. (ANTX), this is critical, as labor-intensive clinical trials require a constant influx of capital. The presence of reserves ensures payment for physicians' work during the automated synthesis of drugs.